GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

The European Commission has approved the expanded use of GSK PLC (LSE:GSK, NYSE:GSK)'s Arexvy, its respiratory syncytial virus (RSV) vaccine, to include adults aged 50 to 59 at increased risk due to underlying medical conditions. It allows for the jab's use ahead of the upcoming RSV season across Europe.

GSK: European Union approves label expansion for RSV jab

GSK shares jumped Wednesday on news Delaware's top court ruled in the pharmaceutical company's favor, by agreeing to review the admissibility of expert evidence that could play a part in the British firm's legal fight against claims its Zantac heartburn drug causes cancer.

GSK shares jump on win in Delaware court over ongoing Zantac battle

GSK PLC (LSE:GSK, NYSE:GSK) shares opened higher after Delaware's Supreme Court said it will hear an appeal by the UK drug market and other pharmaceutical companies, including Pfizer, Sanofi, and Boehringer Ingelheim, to dismiss over 70,000 lawsuits alleging that the discontinued heartburn drug Zantac causes cancer. The companies argue that the scientific methods used by plaintiffs to link Zantac to cancer are unsound.

GSK shares higher after Delaware Zantac ruling

On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a more prominent player in the global cancer therapeutics market. So, the total revenue of GSK's oncology franchise amounted to $450 million for the three months ended June 30, 2024, increasing by 136.8% year-on-year.

GSK's Q2 Success Amid Challenges: What Investors Need To Know

RICHMOND, Calif.--(BUSINESS WIRE)-- #aging--BioAge Labs, Inc. (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the appointment of Jean-Pierre Garnier, PhD, as Chair of the company's Board of Directors. Garnier will succeed current Board Chair James Healy, MD, PhD, managing partner of Sofinnova Investments, who will remain on the Board. “We are excited to welcome JP to BioAge's.

BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors

The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.

GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag

GSK PLC (LSE:GSK, NYSE:GSK) has received the green light for a speedier US regulatory process for a potential new cancer drug being developed with a Chinese partner. The pharmaceuticals developer said it has received 'breakthrough therapy designation' from the US Food and Drug Administration (FDA) for the antibody-drug conjugate to treat relapsed or refractory extensive-stage small-cell lung cancer, an aggressive form of lung cancer.

GSK gets fast-track approval from FDA for Chinese lung cancer drug

AstraZeneca

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Novartis

Pfizer

Roche Holding AG

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

British pharma multinational GSK PLC (LSE:GSK, NYSE:GSK) has persistently been undervalued against its international peer set due to merited fears over the high-profile Zantac litigation. But with recent victories in the US courts, is this discount beginning to look unfair?

GSK's discount unwarranted, especially with latest Zantac win, says broker

British drugmaker GSK said on Friday it would seek a dismissal of an upcoming Zantac case in Florida, where plaintiffs alleged that its discontinued heart burn drug had caused prostate cancer.

GSK to seek dismissal of Florida case against heartburn drug Zantac

GSK PLC (LSE:GSK, NYSE:GSK) has secured a legal victory in the ongoing Zantac (ranitidine) litigation, with the Florida State court in the US excluding the plaintiffs' expert testimony as unreliable. Thousands of lawsuits have been filed against the British drugmaker alleging that the Zantac heartburn medication's active ingredient ranitidine causes cancer.

GSK wins favourable ruling in US Zantac litigation

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

GSK (GSK) is a Top-Ranked Momentum Stock: Should You Buy?

Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV.

German panel endorses GSK, Pfizer RSV vaccines for elderly

Broadstone Net Lease

Bank of Nova Scotia

BRT Apartments

Cardinal Health

Canadian Imperial Bank of Commerce

Cisco Systems

Eastman Chemical

Gap Inc

Iron Mountain

Illinois Tool Works

Coca-Cola

Leggett & Platt

Main Street Capital

Medtronic

Medical Properties Trust

National Grid

NetApp

Realty Income Corp

Orion Office REIT

Oracle

Paramount Global

Philip Morris

Invesco S&P 500 High Dividend Low Volatility ETF

In July, we (my wife and I) received a dividend income total of $2,836.82. 2023 was up 24%. 7 months down in 2024 and the S&P 500 is still up almost 13%, despite the recent sell-offs. We have a high likelihood of a rate cut in September, but too much speculation is happening beyond that date. Time is ticking on that FOMC meeting.

Dividend Income: Lanny's July 2024 Summary

GSK is a pharmaceutical company with key segments in specialty medicine, general medicine, and vaccines. Economic uncertainties arise from political forces, inflation rates and signs of a recession, making the investment scene greatly volatile. Yet, GSK's positioning as a healthcare company, strategic acquisitions, robust financials, strong portfolio in various diseases and healthy margins amidst undervaluation makes it viable investment for steady, upside returns.

GSK: Robust Financials, Strong Portfolio And Sector Rotation To Defensives Make It A Buy

GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury found that the product was not responsible for plaintiff Carrie Joiner's colorectal cancer. Joiner had alleged that she developed cancer from a carcinogenic contaminant called NDMA in the blockbuster pill.

GSK wins Illinois court battle

GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company spokesperson said.

GSK wins latest trial over Zantac cancer claims

India's GlaxoSmithKline Pharmaceuticals reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines.

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand

The US Food and Drug Administration (FDA) has expanded the approval of GSK PLC (LSE:GSK, NYSE:GSK)'s Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This includes patients with mismatch repair proficient or microsatellite stable tumours, which account for the majority of endometrial cancer cases.

GSK cancer drug receives expanded approval from the US regulator

UK-based Pharma giant GSK plc reported its Q2 earnings earlier today. GSK plc exceeded Q2 2024 expectations with revenue up 13%, operating profit up 18%, and EPS up 17%. GSK upgraded full-year guidance with 7-9% top-line growth forecasts, >10% growth in operating profit, and >10% EPS growth.

GSK Q2 Earnings Review: Vaccine Issues Aside, A Strong Quarter

GSK's H1 2024 earnings report is strong, with healthy sales growth, solid core EPS increase, and upgraded outlook, resulting in attractive market multiples. However, the outlook still indicates that investors need to brace for a weak H2 2024, with Arexvy's sales worth watching out for after they slipped up in H1 2024. Along with the potential negative impact from further developments in Zantac trials, the expected disappointing earnings figures indicate risks to price over the coming months.

GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)

GSK plc (NYSE:GSK ) Q2 2024 Earnings Conference Call July 31, 2024 7:00 AM ET Company Participants Nick Stone - Head, IR Emma Walmsley - CEO Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcare Julie Brown - CFO Conference Call Participants Peter Verdult - Citi Peter Welford - Jefferies James Gordon - JPMorgan Richard Parkes - BNP Paribas Graham Parry - Bank of America Merrill Lynch Tim Anderson - Wolfe Research Mark Purcell - Morgan Stanley Emily Field - Barclays Simon Baker - Redburn Atlantic Nick Stone Hello everyone. Welcome to today's call and webcast.

GSK plc (GSK) Q2 2024 Earnings Call Transcript

Around £1.2 billion was wiped from the value of GSK PLC (LSE:GSK, NYSE:GSK) after the drug giant's Q2 vaccine sales failed to pass muster with the City. Specifically, analysts at Shore Capital said the Shingrix, its shingles jab, "missed materially", while there was also some 'harrumphing' around the performance of its RSV inoculation, Arexvy.

GSK sees £1.2bn wiped from its value as investors grumble about vaccine miss

GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.

GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance

GSK (GSK) lifted its sales and earnings projections for the year, after a strong performance by its HIV and cancer drugs drove second-quarter sales higher.

GSK Becomes Latest Pharma Firm To Lift Outlook

News for GlaxoSmithKline Stock (GSK)